Rarity Therapeutics raised $4.6 million to advance RDP-101, an ex vivo autologous hematopoietic stem cell gene therapy designed to restore immune function in patients with rare genetic diseases such as ADA-SCID.
Rarity Therapeutics raised $4.6 million to advance RDP-101, an ex vivo autologous hematopoietic stem cell gene therapy designed to restore immune function in patients with rare genetic diseases such as ADA-SCID.